Alethia Biotherapeutics (Canada), a preclinical-stage biotechnology company focused on bone degredation, closed a $4.7M Series B financing. Participants include AgeChem Venture Fund, BDC Venture Capital and GO Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account […]
Graftys (France) a commercial-stage medical device company focused on minimally invasive femoroplasty using bisphosphonateloaded synthetic bone substitute to prevent contralateral hip fracture after osteoporotic fracture, closed a $5.3M Series C financing. Participants include Ventech, Octalfa, Oreo Finances and Viveris Management.